In vitro tests reveal Myxin's strong antibacterial activity and efficacy against Nontuberculous mycobacteria, indicating its potential for treating infections.
Nontuberculous mycobacteria (NTM) infections, especially those caused by Mycobacterium abscessus , are extremely difficult to treat due to the organisms' intrinsic resistance to many antimicrobials. Myxin is a naturally occurring phenazine‐5,10‐dioxide antibiotic from Sorangium sp., notable for its broad‐spectrum antimicrobial activity. In this study, we determined the susceptibilities of Myxin against 11 NTM reference strains and 194 clinical M. abscessus isolates using microdilution assays. Additionally, time‐kill kinetic experiments were performed to distinguish the clearing efficiency of Myxin in broth. We also evaluated the efficacy of Myxin against intracellular M. abscessus in THP‐1 macrophages. Checkerboard assays assessed the interactions between Myxin and eight clinically important anti‐NTM antibiotics. Myxin demonstrated potent activity against M. abscessus with low MIC values (MIC 50 = 0.125 mg/L and MIC 90 = 0.5 mg/L). Treatment with 20 × MIC of Myxin in 7H9 broth resulted in up to 10 log 10 CFU/mL reduction after 4 days of incubation. An intracellular concentration‐dependent bactericidal effect of Myxin was observed in THP‐1 macrophages. Myxin exhibited no antagonism in combination with standard anti‐NTM drugs. As such, Myxin represents a promising candidate for the treatment of M. abscessus and other NTM infections.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: